Related Experiment Video
Updated: Aug 29, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy
Yoon Kyung Park1, Paramesh Jangili2, Soyu Zi2
1Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. dkim@khu.ac.kr.
Chemical Communications (Cambridge, England)
|September 9, 2022
Abstract:
A new conjugate formulation, SIWV-PB-SN, based on glioblastoma (GBM)-homing SIWV tetrapeptide and an ROS-responsive prodrug is reported. SIWV-PB-SN selectively penetrates the GBM cells and releases anti-GBM drug (SN-38) via ROS-induced linker cleavage. This study presents a new insight for a more advanced therapeutic approach to overcoming GBM.
